ROIV
insider transactionsRoivant Sciences Ltd. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
-8.4M
0 buy · 8.4M sell
Net value · 365d
-$226.3M
$0 in · $226.3M out
Sentiment · 365d
Net selling
0% buying · 100% selling
Open-market trades · 365d
27
0 buy · 8.4M sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Exercise·M
Eric Venker KEY
President & Immunovant CEO · 10b5-1
$0
200.0K sh
Own +5%
-
Sell·S
Eric Venker KEY
President & Immunovant CEO · 10b5-1
$6.1M
200.0K sh · $30.27
Own -11%
-
Exercise·M
Eric Venker KEY
President & Immunovant CEO · 10b5-1
$770.0K
200.0K sh · $3.85
Own +12%
-
Other·F
Eric Venker KEY
President & Immunovant CEO · 10b5-1
$1.1M
34.5K sh · $32.41
Own -2%
-
Other·F
Richard Pulik KEY
CFO
$614.6K
19.0K sh · $32.41
Own -6%
-
Exercise·M
Eric Venker KEY
President & Immunovant CEO · 10b5-1
$0
200.0K sh
Own +4%
-
Sell·S
Eric Venker KEY
President & Immunovant CEO · 10b5-1
$5.9M
200.0K sh · $29.59
Own -11%
-
Exercise·M
Eric Venker KEY
President & Immunovant CEO · 10b5-1
$770.0K
200.0K sh · $3.85
Own +12%
-
Grant·A
Richard Pulik KEY
CFO
$0
84.0K sh
Own New
-
Grant·A
Richard Pulik KEY
CFO
$0
60.6K sh
Own +26%
-
Grant·A
Chief Accounting Officer
$0
27.2K sh
Own New
-
Grant·A
Chief Accounting Officer
$0
29.2K sh
Own +35%
-
Other·F
Director
$2.8K
95 sh · $29.83
Own -0%
-
Grant·A
Director
$0
896 sh
Own +1%
-
Other·F
Director
$2.8K
94 sh · $29.83
Own -0%
-
Grant·A
Director
$0
469 sh
Own +0%
-
Grant·A
Director
$0
670 sh
Own +4%
-
Sell·S
Matthew Gline KEY
CEO
$8.4M
289.8K sh · $29.16
Own -2%
-
Sell·S
Chief Accounting Officer
$384.1K
13.5K sh · $28.37
Own -14%
-
Other·F
Mayukh Sukhatme KEY
President & CIO
$5.2M
187.5K sh · $27.70
Own -1%
-
Other·F
Matthew Gline KEY
CEO
$8.4M
304.7K sh · $27.70
Own -2%
-
Other·F
Frank Torti KEY
President and Vant Chair
$4.4M
160.0K sh · $27.70
Own -1%
-
Exercise·M
Mayukh Sukhatme KEY
President & CIO
$15.0M
1.3M sh · $11.50
Own New
-
Other·F
Mayukh Sukhatme KEY
President & CIO
$787.3K
29.8K sh · $26.41
Own -0%
-
Exercise·M
Mayukh Sukhatme KEY
President & CIO
—
58.4K sh
Own +0%
-
Exercise·M
Matthew Gline KEY
CEO
$25.0M
2.2M sh · $11.50
Own New
-
Other·F
Matthew Gline KEY
CEO
$1.4M
53.8K sh · $26.41
Own -0%
-
Exercise·M
Matthew Gline KEY
CEO
—
97.3K sh
Own +1%
-
Other·F
Richard Pulik KEY
CFO
$42.8K
1.5K sh · $27.70
Own -1%
-
Other·F
Chief Accounting Officer
$402.4K
14.5K sh · $27.70
Own -13%
-
Exercise·M
Eric Venker KEY
President & Immunovant CEO · 10b5-1
$0
200.0K sh
Own +4%
-
Sell·S
Eric Venker KEY
President & Immunovant CEO · 10b5-1
$5.6M
200.0K sh · $28.24
Own -11%
-
Exercise·M
Eric Venker KEY
President & Immunovant CEO · 10b5-1
$770.0K
200.0K sh · $3.85
Own +12%
-
Sell·S
Director
$1.2M
41.9K sh · $28.68
Own -73%
-
Exercise·M
Frank Torti KEY
President and Vant Chair · 10b5-1
$0
587.4K sh
Own +24%
-
Sell·S
Frank Torti KEY
President and Vant Chair · 10b5-1
$16.2M
587.4K sh · $27.51
Own -4%
-
Exercise·M
Frank Torti KEY
President and Vant Chair · 10b5-1
$2.3M
587.4K sh · $3.85
Own +4%
-
Exercise·M
Frank Torti KEY
President and Vant Chair · 10b5-1
$0
1.0M sh
Own +39%
-
Sell·S
Frank Torti KEY
President and Vant Chair · 10b5-1
$27.5M
1.0M sh · $27.15
Own -7%
-
Exercise·M
Frank Torti KEY
President and Vant Chair · 10b5-1
$3.9M
1.0M sh · $3.85
Own +7%
-
Other·F
Eric Venker KEY
President & Immunovant CEO
$191.4K
7.1K sh · $27.15
Own -0%
-
Other·F
Richard Pulik KEY
CFO
$27.1K
1.0K sh · $27.15
Own -0%
-
Exercise·M
Frank Torti KEY
President and Vant Chair · 10b5-1
$0
1.4M sh
Own +43%
-
Sell·S
Frank Torti KEY
President and Vant Chair · 10b5-1
$38.4M
1.4M sh · $27.42
Own -9%
-
Exercise·M
Frank Torti KEY
President and Vant Chair · 10b5-1
$5.4M
1.4M sh · $3.85
Own +10%
-
Sell·S
Other
$6.0M
225.0K sh · $26.50
Own -1%
-
Sell·S
Other
$4.0M
150.8K sh · $26.49
Own -1%
-
Sell·S
Director
$6.0M
225.0K sh · $26.50
Own -1%
-
Sell·S
Director
$4.0M
150.8K sh · $26.49
Own -1%
-
Sell·S
Director
$6.0M
225.0K sh · $26.50
Own -1%
-
Sell·S
Director
$4.0M
150.8K sh · $26.49
Own -1%
-
Exercise·M
Eric Venker KEY
President & Immunovant CEO · 10b5-1
$0
200.0K sh
Own +4%
-
Sell·S
Eric Venker KEY
President & Immunovant CEO · 10b5-1
$5.3M
200.0K sh · $26.49
Own -11%
-
Exercise·M
Eric Venker KEY
President & Immunovant CEO · 10b5-1
$770.0K
200.0K sh · $3.85
Own +12%
-
Sell·S
Other
$7.4M
275.0K sh · $26.76
Own -2%
-
Sell·S
Other
$4.0M
150.0K sh · $26.72
Own -1%
-
Sell·S
Director
$7.4M
275.0K sh · $26.76
Own -2%
-
Sell·S
Director
$4.0M
150.0K sh · $26.72
Own -1%
-
Sell·S
Director
$7.4M
275.0K sh · $26.76
Own -2%
-
Sell·S
Director
$4.0M
150.0K sh · $26.72
Own -1%
-
Sell·S
Other
$11.3M
425.0K sh · $26.67
Own -3%
-
Sell·S
Director
$11.3M
425.0K sh · $26.67
Own -3%
-
Sell·S
Director
$11.3M
425.0K sh · $26.67
Own -3%
-
Exercise·M
Mayukh Sukhatme KEY
President & CIO
$0
651.6K sh
Own New
-
Other·J
Mayukh Sukhatme KEY
President & CIO
$8.3M
312.1K sh · $26.47
-
Sell·S
Mayukh Sukhatme KEY
President & CIO
$9.0M
339.4K sh · $26.47
Own -2%
-
Exercise·M
Mayukh Sukhatme KEY
President & CIO
$8.3M
651.6K sh · $12.68
Own +3%
-
Other·F
Director
$2.8K
124 sh · $22.98
Own -0%
-
Grant·A
Director
$0
1.2K sh
Own +1%
-
Other·F
Director
$2.8K
122 sh · $22.98
Own -0%
-
Grant·A
Director
$0
609 sh
Own +1%
-
Other·F
Director
$1.2K
54 sh · $22.98
Own -0%
-
Grant·A
Director
$0
815 sh
Own +1%
-
Exercise·M
Eric Venker KEY
President & Immunovant CEO · 10b5-1
$0
200.0K sh
Own +4%
-
Sell·S
Eric Venker KEY
President & Immunovant CEO · 10b5-1
$4.4M
200.0K sh · $21.92
Own -11%
-
Exercise·M
Eric Venker KEY
President & Immunovant CEO · 10b5-1
$770.0K
200.0K sh · $3.85
Own +12%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| May 22, 2026 | Eric Venker KEY 10b5-1 | Exercise M | 200.0K | $0 |
| May 22, 2026 | Eric Venker KEY 10b5-1 | Sell S | 200.0K | $6.1M |
| May 22, 2026 | Eric Venker KEY 10b5-1 | Exercise M | 200.0K | $770.0K |
| May 20, 2026 | Eric Venker KEY 10b5-1 | Other F | 34.5K | $1.1M |
| May 20, 2026 | Richard Pulik KEY | Other F | 19.0K | $614.6K |
| Apr 20, 2026 | Eric Venker KEY 10b5-1 | Exercise M | 200.0K | $0 |
| Apr 20, 2026 | Eric Venker KEY 10b5-1 | Sell S | 200.0K | $5.9M |
| Apr 20, 2026 | Eric Venker KEY 10b5-1 | Exercise M | 200.0K | $770.0K |
| Apr 20, 2026 | Richard Pulik KEY | Grant A | 84.0K | $0 |
| Apr 20, 2026 | Richard Pulik KEY | Grant A | 60.6K | $0 |
| Apr 20, 2026 | Jennifer Humes | Grant A | 27.2K | $0 |
| Apr 20, 2026 | Jennifer Humes | Grant A | 29.2K | $0 |
| Apr 17, 2026 | Ilan Oren | Other F | 95 | $2.8K |
| Apr 17, 2026 | Ilan Oren | Grant A | 896 | $0 |
| Apr 17, 2026 | James C Momtazee | Other F | 94 | $2.8K |
| Apr 17, 2026 | James C Momtazee | Grant A | 469 | $0 |
| Apr 17, 2026 | Melissa B, Epperly | Grant A | 670 | $0 |
| Apr 16, 2026 | Matthew Gline KEY | Sell S | 289.8K | $8.4M |
| Apr 8, 2026 | Jennifer Humes | Sell S | 13.5K | $384.1K |
| Mar 31, 2026 | Mayukh Sukhatme KEY | Other F | 187.5K | $5.2M |
| Mar 31, 2026 | Matthew Gline KEY | Other F | 304.7K | $8.4M |
| Mar 31, 2026 | Frank Torti KEY | Other F | 160.0K | $4.4M |
| Mar 30, 2026 | Mayukh Sukhatme KEY | Exercise M | 1.3M | $15.0M |
| Mar 30, 2026 | Mayukh Sukhatme KEY | Other F | 29.8K | $787.3K |
| Mar 30, 2026 | Mayukh Sukhatme KEY | Exercise M | 58.4K | — |
| Mar 30, 2026 | Matthew Gline KEY | Exercise M | 2.2M | $25.0M |
| Mar 30, 2026 | Matthew Gline KEY | Other F | 53.8K | $1.4M |
| Mar 30, 2026 | Matthew Gline KEY | Exercise M | 97.3K | — |
| Mar 20, 2026 | Richard Pulik KEY | Other F | 1.5K | $42.8K |
| Mar 20, 2026 | Jennifer Humes | Other F | 14.5K | $402.4K |
| Mar 17, 2026 | Eric Venker KEY 10b5-1 | Exercise M | 200.0K | $0 |
| Mar 17, 2026 | Eric Venker KEY 10b5-1 | Sell S | 200.0K | $5.6M |
| Mar 17, 2026 | Eric Venker KEY 10b5-1 | Exercise M | 200.0K | $770.0K |
| Mar 16, 2026 | Melissa B, Epperly | Sell S | 41.9K | $1.2M |
| Feb 23, 2026 | Frank Torti KEY 10b5-1 | Exercise M | 587.4K | $0 |
| Feb 23, 2026 | Frank Torti KEY 10b5-1 | Sell S | 587.4K | $16.2M |
| Feb 23, 2026 | Frank Torti KEY 10b5-1 | Exercise M | 587.4K | $2.3M |
| Feb 20, 2026 | Frank Torti KEY 10b5-1 | Exercise M | 1.0M | $0 |
| Feb 20, 2026 | Frank Torti KEY 10b5-1 | Sell S | 1.0M | $27.5M |
| Feb 20, 2026 | Frank Torti KEY 10b5-1 | Exercise M | 1.0M | $3.9M |
| Feb 20, 2026 | Eric Venker KEY | Other F | 7.1K | $191.4K |
| Feb 20, 2026 | Richard Pulik KEY | Other F | 1.0K | $27.1K |
| Feb 19, 2026 | Frank Torti KEY 10b5-1 | Exercise M | 1.4M | $0 |
| Feb 19, 2026 | Frank Torti KEY 10b5-1 | Sell S | 1.4M | $38.4M |
| Feb 19, 2026 | Frank Torti KEY 10b5-1 | Exercise M | 1.4M | $5.4M |
| Feb 13, 2026 | QVT Financial LP | Sell S | 225.0K | $6.0M |
| Feb 13, 2026 | QVT Financial LP | Sell S | 150.8K | $4.0M |
| Feb 13, 2026 | Keith S Manchester | Sell S | 225.0K | $6.0M |
| Feb 13, 2026 | Keith S Manchester | Sell S | 150.8K | $4.0M |
| Feb 13, 2026 | Daniel Allen Gold | Sell S | 225.0K | $6.0M |
| Feb 13, 2026 | Daniel Allen Gold | Sell S | 150.8K | $4.0M |
| Feb 13, 2026 | Eric Venker KEY 10b5-1 | Exercise M | 200.0K | $0 |
| Feb 13, 2026 | Eric Venker KEY 10b5-1 | Sell S | 200.0K | $5.3M |
| Feb 13, 2026 | Eric Venker KEY 10b5-1 | Exercise M | 200.0K | $770.0K |
| Feb 12, 2026 | QVT Financial LP | Sell S | 275.0K | $7.4M |
| Feb 12, 2026 | QVT Financial LP | Sell S | 150.0K | $4.0M |
| Feb 12, 2026 | Keith S Manchester | Sell S | 275.0K | $7.4M |
| Feb 12, 2026 | Keith S Manchester | Sell S | 150.0K | $4.0M |
| Feb 12, 2026 | Daniel Allen Gold | Sell S | 275.0K | $7.4M |
| Feb 12, 2026 | Daniel Allen Gold | Sell S | 150.0K | $4.0M |
| Feb 11, 2026 | QVT Financial LP | Sell S | 425.0K | $11.3M |
| Feb 11, 2026 | Keith S Manchester | Sell S | 425.0K | $11.3M |
| Feb 11, 2026 | Daniel Allen Gold | Sell S | 425.0K | $11.3M |
| Feb 9, 2026 | Mayukh Sukhatme KEY | Exercise M | 651.6K | $0 |
| Feb 9, 2026 | Mayukh Sukhatme KEY | Other J | 312.1K | $8.3M |
| Feb 9, 2026 | Mayukh Sukhatme KEY | Sell S | 339.4K | $9.0M |
| Feb 9, 2026 | Mayukh Sukhatme KEY | Exercise M | 651.6K | $8.3M |
| Jan 20, 2026 | Ilan Oren | Other F | 124 | $2.8K |
| Jan 20, 2026 | Ilan Oren | Grant A | 1.2K | $0 |
| Jan 20, 2026 | James C Momtazee | Other F | 122 | $2.8K |
| Jan 20, 2026 | James C Momtazee | Grant A | 609 | $0 |
| Jan 20, 2026 | Melissa B, Epperly | Other F | 54 | $1.2K |
| Jan 20, 2026 | Melissa B, Epperly | Grant A | 815 | $0 |
| Jan 12, 2026 | Eric Venker KEY 10b5-1 | Exercise M | 200.0K | $0 |
| Jan 12, 2026 | Eric Venker KEY 10b5-1 | Sell S | 200.0K | $4.4M |
| Jan 12, 2026 | Eric Venker KEY 10b5-1 | Exercise M | 200.0K | $770.0K |
About ROIV insider trading
This page tracks insider transactions for Roivant Sciences Ltd. (ROIV) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.